Evidence map›Paper›PMID 32880824›Full record

ArticleInternational journal of hematology2020

Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.

Shinichiro Matsuda, Ritsuro Suzuki, Tsutomu Takahashi, Youko Suehiro, Naoto Tomita, Koji Izutsu, Noriko Fukuhara, Yoshitaka Imaizumi, Kazuyuki Shimada, Tomonori Nakazato and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shinichiro MatsudaInnovative Cancer Center/Oncology-Hematology, Shimane University Hospital, 89-1 Enya, Izumo, Shimane, 693-8501, Japan.
Ritsuro SuzukiInnovative Cancer Center/Oncology-Hematology, Shimane University Hospital, 89-1 Enya, Izumo, Shimane, 693-8501, Japan.
Tsutomu TakahashiInnovative Cancer Center/Oncology-Hematology, Shimane University Hospital, 89-1 Enya, Izumo, Shimane, 693-8501, Japan.
Youko SuehiroDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Naoto TomitaDepartment of Hematology, St. Marianna University School of Medicine, Kawasaki, Japan.
Koji IzutsuDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Noriko FukuharaDepartment of Hematology, Tohoku University Hospital, Sendai, Japan.
Yoshitaka ImaizumiDepartment of Hematology, Nagasaki University, Nagasaki, Japan.
Kazuyuki ShimadaDepartment of Hematology, Nagoya University Hospital, Nagoya, Japan.
Tomonori NakazatoDepartment of Hematology, Yokohama Municipal Citizens Hospital, Yokohama, Japan.
Isao YoshidaDepartment of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
Kana MiyazakiDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Motoko YamaguchiDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Junji SuzumiyaInnovative Cancer Center/Oncology-Hematology, Shimane University Hospital, 89-1 Enya, Izumo, Shimane, 693-8501, Japan. suzumiya@med.shimane-u.ac.jp.

Funding

Japan Agency for Medical Research and Development (JP) JP18ck0106439, J.S.
6 · The paper itself

Abstract

CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) -/+ rituximab (R) is the standard chemotherapeutic regimen for aggressive lymphoma, but is insufficient for aggressive lymphoma with adverse prognostic factors. Dose-adjusted (DA)-EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisolone) -/+ R demonstrates excellent efficacy against some aggressive lymphoma. Thus, we conducted a retrospective study to evaluate the feasibility and efficacy of this therapy in clinical practice. We enrolled 149 patients from 17 institutions diagnosed between 2007 and 2015. The median follow-up period for survivors was 27 months (range 0.2-123). The complete response (CR) rate of newly diagnosed patients was 79% (95% CI 68-87%). All patients were hospitalized to receive this therapy and 94% of patients also received granulocyte-colony-stimulating factor support. There were no treatment-related deaths. Febrile neutropenia (FN) and grade 3 or 4 infection occurred in 55% and 28% of patients, respectively. There were no significant differences in FN or infection between young (≤ 65 years) and elderly patients (> 65 years). In newly diagnosed diffuse large B-cell lymphoma-not otherwise specified patients (n = 46), the CR rate was 80% (95% CI 64-91%) and the 2-year OS rate was 81% (95% CI 66-90%). In the present study, DA-EPOCH -/+ R exhibited excellent efficacy and feasibility for aggressive lymphoma.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCommunicable DiseasesCyclophosphamideDoxorubicinEtoposideFeasibility StudiesFebrile NeutropeniaFemaleGranulocyte Colony-Stimulating FactorHumansLymphomaMaleCyclophosphamideDoxorubicinEtoposideGranulocyte Colony-Stimulating FactorPrednisoneRituximabVincristineDA-EPOCHDLBCLLymphoma

Identifiers

PMID32880824

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.